1322 related articles for article (PubMed ID: 27616593)
1. Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R
Lancet; 2016 Nov; 388(10059):2532-2561. PubMed ID: 27616593
[TBL] [Abstract][Full Text] [Related]
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2002 Jul; 360(9326):7-22. PubMed ID: 12114036
[TBL] [Abstract][Full Text] [Related]
3. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
Collins R; Armitage J; Parish S; Sleight P; Peto R;
Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
[TBL] [Abstract][Full Text] [Related]
4. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R; Armitage J; Parish S; Sleigh P; Peto R;
Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
8. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
; Baigent C; Blackwell L; Emberson J; Holland LE; Reith C; Bhala N; Peto R; Barnes EH; Keech A; Simes J; Collins R
Lancet; 2010 Nov; 376(9753):1670-81. PubMed ID: 21067804
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
11. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration
Lancet; 2019 Feb; 393(10170):407-415. PubMed ID: 30712900
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
14. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
; Armitage J; Bowman L; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Peto R; Collins R
Lancet; 2010 Nov; 376(9753):1658-69. PubMed ID: 21067805
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
; Fulcher J; O'Connell R; Voysey M; Emberson J; Blackwell L; Mihaylova B; Simes J; Collins R; Kirby A; Colhoun H; Braunwald E; La Rosa J; Pedersen TR; Tonkin A; Davis B; Sleight P; Franzosi MG; Baigent C; Keech A
Lancet; 2015 Apr; 385(9976):1397-405. PubMed ID: 25579834
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.
Heart Protection Study Collaborative Group
J Vasc Surg; 2007 Apr; 45(4):645-654; discussion 653-4. PubMed ID: 17398372
[TBL] [Abstract][Full Text] [Related]
17. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
März W; Wollschläger H; Klein G; Neiss A; Wehling M
Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
[TBL] [Abstract][Full Text] [Related]
18. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
[TBL] [Abstract][Full Text] [Related]
19. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
